Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry

Medical Physics

Volumn 35, Issue 3, 2008, Pages 1123-1134

  Baechler, Sébastien ^a,b   Hobbs, Robert F ^a   Prideaux, Andrew R ^a   Wahl, Richard L ^a   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Biological effective dose; Dosimetry; Radionuclide therapy

Indexed keywords

DOSIMETRY; HOSPITAL DATA PROCESSING; PATIENT TREATMENT; RADIOISOTOPES; TISSUE; TISSUE REGENERATION; TOXICITY;

BIOLOGICAL EFFECTIVE DOSE; BIOLOGICAL IMPACTS; DOSE IRRADIATION; INITIAL ACTIVITY; PATIENT SPECIFIC; RADIOBIOLOGICAL MODELING; RADIONUCLIDE THERAPY; TREATMENT PLANNING;

BIOLOGICAL ORGANS;

DOTATATE LU 177; DOTATOC Y 90; PENTETREOTIDE IN 111; RADIOACTIVE IODINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; THYROTROPIN; UNCLASSIFIED DRUG;

ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DOSIMETRY; DRUG CLEARANCE; DRUG SAFETY; KIDNEY CORTEX; KIDNEY MEDULLA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TREATMENT PLANNING;

EID: 40049084212     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.2836421     Document Type: Article

References (35)